Quarterly report [Sections 13 or 15(d)]

Revenues from Contracts and Significant Customers (Tables)

v3.26.1
Revenues from Contracts and Significant Customers (Tables)
3 Months Ended
Mar. 31, 2026
Revenues from Contracts and Significant Customers  
Schedule of disaggregation of total revenues

​

​

​

​

​

​

​

​

​

​

Three Months Ended March 31, 

($ in thousands)

  ​ ​ ​

2026

  ​ ​ ​

2025

Emrosi

​

$

6,252

​

$

2,070

Qbrexza

​

​

5,028

​

​

5,161

Accutane

​

​

3,314

​

​

3,655

Foam franchise products (Amzeeq & Zilxi)

​

​

1,050

​

​

1,526

Other / legacy product revenue

​

​

277

​

​

727

Other revenue

​

​

117

​

 

—

Total net revenue

​

$

16,038

​

$

13,139